GH replacement therapy aims to normalize endogenous IGF-I concentrations, whereas effective treatment in individuals with acromegaly is reflected by decreasing IGF-I concentrations (Kargi and Merriam, 2013; Katznelson et al., 2011). The gene discussed is GH1; the disease is acromegaly.